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Release of Active Peptidyl Arginine Deiminases by Neutrophils
Can Explain Production of Extracellular Citrullinated
Autoantigens in Rheumatoid Arthritis Synovial Fluid
Julia Spengler,1 Bozo Lugonja,1 A. Jimmy Ytterberg,2 Roman A. Zubarev,3
Andrew J. Creese,4 Mark J. Pearson,1 Melissa M. Grant,4 Michael Milward,4
Karin Lundberg,2 Christopher D. Buckley,5 Andrew Filer,6 Karim Raza,5
Paul R. Cooper,4 Iain L. Chapple,4 and Dagmar Scheel-Toellner1
Objective. In the majority of patients with rheu-
matoid arthritis (RA), antibodies specifically recognize
citrullinated autoantigens that are generated by peptidy-
larginine deiminases (PADs). Neutrophils express high
levels of PAD and accumulate in the synovial fluid (SF)
of RA patients during disease flares. This study was
undertaken to test the hypothesis that neutrophil cell
death, induced by either NETosis (extrusion of genomic
DNA–protein complexes known as neutrophil extracellu-
lar traps [NETs]) or necrosis, can contribute to produc-
tion of autoantigens in the inflamed joint.
Methods. Extracellular DNA was quantified in the
SF of patients with RA, patients with osteoarthritis (OA),
and patients with psoriatic arthritis (PsA). Release of
PAD from neutrophils was investigated by Western blot-
ting, mass spectrometry, immunofluorescence staining,
and PAD activity assays. PAD2 and PAD4 protein expres-
sion, as well as PAD enzymatic activity, were assessed in
the SF of patients with RA and those with OA.
Results. Extracellular DNA was detected at sig-
nificantly higher levels in RA SF than in OA SF (P <
0.001) or PsA SF (P < 0.05), and its expression levels
correlated with neutrophil concentrations and PAD
activity in RA SF. Necrotic neutrophils released less
soluble extracellular DNA compared to NETotic cells in
vitro (P < 0.05). Higher PAD activity was detected in
RA SF than in OA SF (P < 0.05). The citrullinated pro-
teins PAD2 and PAD4 were found attached to NETs and
also freely diffused in the supernatant. PAD enzymatic
activity was detected in supernatants of neutrophils un-
dergoing either NETosis or necrosis.
Conclusion. Release of active PAD isoforms into
the SF by neutrophil cell death is a plausible explanation
for the generation of extracellular autoantigens in RA.
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The synovial cavity of patients with rheumatoid
arthritis (RA) is infiltrated by large numbers of neutro-
phils. Once activated, neutrophils augment disease devel-
opment and progression through the generation of
reactive oxygen species, proteolytic enzymes, and proin-
flammatory cytokines (1). Several forms of neutrophil
cell death have been described (2), such as apoptosis,
necrosis, and a novel pathway involving extrusion of
genomic DNA–protein complexes known as neutrophil
extracellular traps (NETs), termed NETosis (3). This
complex process involves the active release of genomic
DNA into the extracellular space. The resulting network
of DNA and associated proteins (e.g., histones, myelo-
peroxidase, and neutrophil elastase), or NETs, is pre-
sent in the joints of RA patients (4,5). NETosis involves
activation of peptidylarginine deiminase 4 (PAD4). The
importance of this enzyme to NETosis is underlined by
the observation that neutrophils in PAD4-deficient mice
do not generate NETs upon stimulation (6).
PAD4 belongs to a family of 5 PAD isoforms
whose enzymatic activity leads to deimination of argi-
nine side chains, resulting in protein citrullination. PAD
isoforms are highly homologous and functionally simi-
lar, but differ in their expression pattern throughout
various organ systems and cell types (7). Neutrophils
express PAD2, which is ubiquitously expressed, and
PAD4, which is mainly expressed by myeloid cells (7).
Activation of PAD isoforms is relevant to RA, as spe-
cific autoimmunity to citrullinated proteins has been
observed in ;60% of RA patients (8,9), and this charac-
teristic defines a group of patients with more aggressive
disease and distinct genetic associations.
Anti–citrullinated protein antibodies (ACPAs)
bind a diverse range of citrullinated proteins, and B cell
responses to these modified proteins have been observed
in the rheumatoid joint (10). It is not yet clear whether
neutrophils in the synovial fluid (SF) contribute to the
pool of available extracellular PAD and whether PADs
are enzymatically active. In this context, it is also important
to know whether PAD isoforms are released attached to
the DNA–protein complex of the NETs or whether they
are freely diffusible. Neutrophils are rarely observed in
synovial tissue, whereas they are the most abundant cell
type in the SF (11). If PADs remain tethered to NETs,
this would potentially limit the role of neutrophil-derived
PAD in the SF. However, the lack of a basement mem-
brane or tight junctions in the synovial lining suggests that
soluble, freely diffusible PAD released from neutrophils
within the SF could enter synovial tissue and potentially
contribute to the local production of autoantigens through-
out the inflamed synovium (12).
We therefore investigated the release of PAD and
citrullinated proteins from neutrophils undergoing NETo-
sis and compared this process to necrosis. Moreover, the
localization of PAD within the cells, the levels of PAD
activity in SF from patients with different arthritides, and
the levels of PAD activity in relation to evidence of neutro-
phil infiltration and NETosis were examined.
PATIENTS AND METHODS
Patient selection and sample collection. RA patients
fulfilled the American College of Rheumatology 1987 classifica-
tion criteria for RA (13). Osteoarthritis (OA) of the knee and
psoriatic arthritis (PsA) were diagnosed according to established
criteria (14,15). SF samples were aspirated from the joints of all
patients under manual palpation or ultrasound guidance. Synovi-
al tissue was obtained by ultrasound-guided synovial biopsy (16).
Ethics approval was obtained and all participants gave their writ-
ten informed consent. Details on the demographic and clinical
characteristics of the patients are shown in Table 1.
Reagents. For immunofluorescence staining, we used
antibodies to neutrophil elastase (ab21595; Abcam), combined
with an Alexa Fluor 647–conjugated goat anti-rabbit IgG anti-
body (Jackson ImmunoResearch), and antibodies to PAD4
(ab128086; Abcam), combined with a streptavidin–Alexa Fluor
488–conjugated (Jackson ImmunoResearch) goat anti-mouse
IgG2a biotin antibody (Southern Biotech). Anti-human PAD2
antibodies (ab50257; Abcam) were revealed with an Alexa
Fluor 488–conjugated donkey anti-rabbit IgG antibody (Life
Technologies). Antibodies to CD15 (clone MEM-158; Immu-
notools) or to citrullinated histone H3 (ab5103; Abcam) were
combined with a donkey anti-mouse IgM antibody (Jackson
ImmunoResearch) or an Alexa Fluor 647–conjugated donkey
anti-rabbit IgG antibody (Jackson ImmunoResearch), respec-
tively. All stainings included concentration-, species-, and
isotype-matched control antibodies.
For Western blotting, antibodies specific for neutro-
phil elastase (ab21595; Abcam), antibodies specific for PAD2
(ab50257; Abcam), and 2 monoclonal antibodies to PAD4
(H00023569-M01 from Novus Biologicals and ab128086
from Abcam) were used. All 3 PAD isoform antibodies were
tested to exclude cross-reactivity. Human recombinant PAD4
was purchased from Cayman Chemical (item no. 10500). Sytox
Green was purchased from Invitrogen. Other reagents used
included DNase I (AM2235; Ambion, Applied Biosystems),
placental DNA (D4642; Sigma-Aldrich), and protease inhibi-
tor cocktail (P8340; Sigma-Aldrich).
Neutrophil isolation from peripheral blood. Peripheral
blood from healthy donors was anticoagulated with EDTA
(E7889; Sigma-Aldrich) at a final concentration of 1.5 mM. Neu-
trophils were separated from the peripheral blood using Percoll
discontinuous density gradients, as previously described (17).
Immunofluorescence microscopy. Slide preparations
of SF samples from all patients were created by pipetting 30 ml
SF onto a glass slide. Cells were allowed to sediment for
2 minutes. Supernatant was carefully removed and slides were
left to air dry and frozen at 2208C. SF slide preparations and
5-mm frozen sections from RA synovial tissue were fixed in
4% paraformaldehyde (PFA) for 10 minutes, blocked with
phosphate buffered saline (PBS) with 10% fetal calf serum
(FCS), and incubated with primary antibodies to CD15 or to
neutrophil elastase, diluted in 10% FCS in PBS. Nuclei were
counterstained with Hoechst S769121 (Life Technologies).
For immunofluorescence staining of stimulated cells in
vitro, neutrophils were seeded on coverslips and fixed with 4%
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PFA for 10 minutes after stimulation, and kept overnight at
48C. Coverslips were rinsed with PBS and then blocked for 45
minutes with PBS in 2% bovine serum albumin (BSA), 2%
goat and/or donkey serum, and 0.25% Triton X-100 (3).
Primary antibodies were diluted in PBS with 2% BSA and
0.25% Triton X-100, washed in PBS, revealed using Alexa Fluor–
conjugated secondary antibodies, and counterstained with 10 mg/
ml Hoechst S769121. Images were captured and processed with a
Zeiss confocal LSM 510 laser scanning microscope.
Isolation and quantification of NETs released during
in vitro NETosis, for analysis by Western blotting and mass
spectrometry. Neutrophils isolated from the peripheral blood
of healthy donors were seeded at a concentration of 1 3 106/ml
and stimulated using phorbol myristate acetate (PMA) at a
final concentration of 25 nM for 4 hours at 378C in an atmo-
sphere of 5% CO2. Supernatants of either stimulated or unsti-
mulated neutrophils were harvested, and the wells were
washed 3 times to remove unbound proteins, as described pre-
viously (18). Cell-associated NETs were solubilized with 10
units/ml DNase I for 20 minutes in 500 ml RPMI medium and
protease inhibitor cocktail at a dilution of 1:200 (P8340; Sigma-
Aldrich). The reaction was stopped with 5 mM EDTA. Super-
natants of stimulated or unstimulated neutrophils from all 3
washing steps, as well as supernatants of the DNase I–treated
NET fraction and the untreated control fraction, were collect-
ed. All supernatants were centrifuged for 10 minutes at 300g to
remove whole cells, and for 10 minutes at 16,000g to remove
debris. Proteins were precipitated with a final concentration of
15% weight/volume trichloroacetic acid for 20 minutes on ice,
and then centrifuged for 10 minutes at 16,000g. Pellets were
washed twice with ice-cold acetone.
To quantify DNA, 90 ml of each supernatant was incu-
bated with 10 ml of 10 mM Sytox Green (Invitrogen) at a final
concentration of 1 mM in a black 96-well assay plate (Corning)
and incubated for 10 minutes at room temperature. Fluorescence
intensity readings for DNA quantification were obtained with a
plate reader (BioTek-Synergy 2) at a wavelength of 530 nm, and
the values were compared to a standard curve of values for puri-
fied human DNA (Sigma-Aldrich).
Induction of necrotic cell death in neutrophils. Neu-
trophils were placed in 2-ml polypropylene tubes at a cell concen-
tration of 1 3 106/ml in 1 ml and subjected to 5 freeze–thaw
cycles, as described previously (19). After the last freeze–thaw
cycle, tubes were centrifuged for 10 minutes at 300g to remove
whole cells, and the supernatants were transferred to fresh tubes
and centrifuged a second time for 10 minutes at 16,000g to remove
debris. PAD activity and DNA concentrations were assessed in
supernatants of resting (unstimulated) neutrophils, necrotic neu-
trophils, and neutrophils stimulated with 25 nM PMA to induce
NETosis (all derived from peripheral blood samples from the
same healthy donors).
Western blotting. Protein precipitates were solubilized
in sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer, separated on 12% SDS-PAGE
gels, and transferred to PVDF membranes using a wet blotting
system. Human skeletal muscle tissue was lysed in radioim-
munoprecipitation assay buffer (R0278; Sigma-Aldrich) in combi-
nation with a protease inhibitor cocktail (P8340; Sigma-Aldrich)
and diluted with SDS-PAGE sample buffer after protein quantifi-
cation. After blocking with 5% milk powder in Tris buffered
saline (TBS) with 0.05% Tween 20, membranes were incubated
overnight at 48C with primary antibody and developed with horse-
radish peroxidase (HRP)–conjugated antibody and ECL Plus or
ECL Prime reagents (GE Healthcare, Amersham).
Quantification of extracellular DNA in SF samples
using Sytox Green. Untreated SF samples used immediately
after aspiration from the joints were diluted with PBS to 1:10,
1:100, and 1:1,000, and levels of free DNA were assessed in
the SF in same manner as described above for DNA quantifi-
cation in supernatants, with the fluorescence intensity readings
performed at a wavelength of 530 nm. DNA concentrations
were calculated with reference to a standard curve of values
for purified DNA (Sigma-Aldrich). To obtain cell-free SF, the
samples were centrifuged for 10 minutes at 300g.
Table 1. Demographic and clinical characteristics of the study patients*
Patients with RA Patients with PsA Patients with OA
No. of patients 54 12 20
No. (%) female 36 (67) 4 (33) 13 (65)
Age, median (IQR) years 58 (46–66) 44 (40–50) 63 (52–67)
Disease duration, median (IQR) years 4 (1–9) 9 (5–19) –
No. (%) RF positive 41 (76) 0 (0) –
No. (%) ACPA positive† 35 (73) 0 (0) –
CRP, median (IQR) mg/ml 19 (8–56) 9 (3–10) –
ESR, median (IQR) mm/hour 30 (18–48) 6 (3–9) –
SJC (of 28 joints), median (IQR) 5 (2–7) 1.5 (1–2) –
TJC (of 28 joints), median (IQR) 5 (3–10) 2 (1–4) –
DAS28-ESR, median (IQR) 5 (4–6) 3 (2–3) –
No. (%) receiving DMARDs 40 (74) 9 (75) –
* Not all patient samples were used for the same experiments. For each assay, the maximum number
of patient samples that were available at a given time point were processed. The number of patients
from whom biologic material was obtained for each experiment is indicated throughout the text. RA5
rheumatoid arthritis; PsA5 psoriatic arthritis; OA5osteoarthritis; IQR5 interquartile range; RF5
rheumatoid factor; CRP5C-reactive protein; ESR5 erythrocyte sedimentation rate; SJC5 swollen joint
count; TJC5 tender joint count; DAS28-ESR5Disease Activity Score in 28 joints using the ESR;
DMARDs5 disease-modifying antirheumatic drugs.
† Positivity for anti–citrullinated protein antibodies (ACPAs) was determined using an anti–cyclic
citrullinated peptide test in samples available from 48 of 54 patients.
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Quantification of neutrophils and macrophages in
SF samples. SF samples were stained with Giemsa (Diff-Quick;
Gamidor Technical Services). Thereafter, total cell counts and
the proportion of neutrophils and macrophages within the syno-
vial infiltrate were determined using a hemocytometer and cyto-
spin preparations.
Mass spectrometry analysis. Supernatants and NET
fractions from stimulated neutrophils from 7 healthy donors
were digested by trypsin (20) and analyzed by LTQ OrbitrapVe-
los ETD or by Q Exactive mass spectrometry (Thermo Fisher
Scientific). Data were quantified using Quanti work flow (21).
P values were calculated using Student’s t-test, and expectation
values were calculated by multiplying the P values by the num-
ber of observations (for further details, see Supplementary
Methods, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39313/abstract).
Depletion of albumin from the SF. SF samples were
centrifuged at 300g. Albumin was removed from the superna-
tants using a Maxi ProteoExtract Albumin/IgG Removal Kit
(Calbiochem). The protein concentration in the eluate was
determined using a BCA Protein Assay Kit (Thermo Fisher
Scientific). Twelve micrograms of each sample was diluted
with 53 SDS loading buffer and further used for SDS-PAGE
and Western blotting analyses.
Detection of citrulline modifications. Citrullinated
residues in proteins from neutrophil supernatants blotted on
PVDF membranes were modified using the protocol described
by Senshu et al (22). Briefly, membranes were incubated over-
night at 378C with an end concentration of 0.77 mM FeCl3,
1.47M H3PO4, and 2.25M H2SO4 in combination with 0.25M
C2H4O2, 25 mM 2,3-butanedione monoxime, and 6.64 mM anti-
pyrine. After rinsing with deionized H2O and blocking with 5%
milk powder in TBS with 0.05% Tween 20 the next day, mem-
branes were probed overnight at 48C with a monoclonal human
anti–modified citrulline antibody (clone C4; Modiquest) and
developed with an HRP-conjugated goat anti-human antibody
(Jackson ImmunoResearch) and ECL Prime (GE Healthcare,
Amersham).
PAD activity assay. For analysis of PAD activity
released by stimulated neutrophils in vitro, isolated cells were
seeded at 1 3 106/ml and left to sediment for 1 hour at 378C in
an atmosphere of 5% CO2 in RPMI 1640 medium (Sigma-
Aldrich). After sedimentation, the supernatant was replaced
either with 1 ml prewarmed RPMI medium (unstimulated con-
trol) or with 1 ml of 25 nM PMA in RPMI medium. After stim-
ulation, the supernatants were collected and treated with
protease inhibitor cocktail (diluted 1:100; Sigma-Aldrich) with
an additional 3.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride
hydrochloride on ice. Supernatants were centrifuged at 48C for
5 minutes at 300g to remove residual cells and diluted 1:2 with
deimination buffer (8.58 mM CaCl2, 5 mM dithiothreitol
[DTT], and 40 mM Tris HCl, pH 7.5), which, together with the
0.42 mM calcium in RPMI 1640 medium, resulted in a calcium
concentration of 4.5 mM. Supernatants were transferred to an
Antibody Based Assay for PAD activity (ABAP) (MQ-17.101-
96; ModiQuest Research), incubated for 1.5 hours at 378C, and
further processed according to the manufacturer’s protocol.
RA SF and OA SF were centrifuged to remove cells,
and the supernatants were cryopreserved. To compare PAD
activity at native and artificial calcium concentrations, 100 ml SF
was either loaded into the ABAP assay directly or prediluted
1:100 with deimination buffer (5 mM CaCl2, 1 mM DTT, and
40 mM Tris HCl, pH 7.5).
Statistical analysis. Data were analyzed using Graph-
Pad Prism software (version 5.0). The individual statistical tests
used were the Mann-Whitney U test, Wilcoxon’s matched pairs
signed rank test, and Spearman’s test for correlations. P values
less than 0.05 were considered significant.
RESULTS
Presence of free extracellular DNA in RA SF.
Quantification of extracellular DNA in freshly obtained,
not cryopreserved, SF samples from patients with RA,
patients with OA, and patients with PsA confirmed and
extended previous findings indicating that free extracellu-
lar DNA can be found in RA SF. Samples were com-
pared to a known DNA standard solution in individual
experiments. Significantly higher DNA levels were found
in SF from RA patients compared to SF from patients
with OA (P , 0.001) and patients with PsA (P , 0.05)
(Figure 1A). Furthermore, significantly higher levels of
Figure 1. Presence of extracellular DNA in the synovial fluid (SF)
of patients with rheumatoid arthritis (RA) and correlation with neu-
trophil cell counts. A, Quantification of extracellular DNA concen-
trations (conc) in the SF of patients with RA (n5 54), patients with
psoriatic arthritis (PsA) (n5 12), and patients with osteoarthritis
(OA) (n5 15). Freshly isolated neutrophils from the peripheral
blood (PB) of healthy donors (n5 6) were used as a negative con-
trol. B, Comparison of free DNA levels in the SF between anti–
citrullinated protein antibody (ACPA)–positive and ACPA-negative
RA patients. In A and B, symbols represent individual patients; hori-
zontal bars show the median. *5P , 0.05; **5P , 0.01; ***5P ,
0.001, by Mann-Whitney U test. C and D, Assessment of correlations
between DNA levels and the neutrophil concentration (C) and macro-
phage concentration (D) in the SF of 20 RA patients. Correlations
were determined by Spearman’s rho test.
3138 SPENGLER ET AL
extracellular DNA were detected in SF from ACPA-
positive RA patients compared to ACPA-negative RA
patients (P , 0.05) (Figure 1B). A small number of
patients with different types of inflammatory arthritis,
such as gout (n5 2), pseudogout (n5 1), or reactive
arthritis (n5 1), showed variable levels of extracellular
DNA in the SF (data not shown).
Validation experiments in which the DNA con-
centration in untreated SF samples (n5 12) was mea-
sured before and after centrifugation of the cells
showed that 78% of the signal (interquartile range 66–
89%) was derived from cell-free SF samples, suggesting
that necrotic cells with permeable membranes contrib-
uted only a small proportion of the DNA signal (see
Supplementary Figure 1A, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39313/abstract). In parallel experiments,
the release of free extracellular DNA was compared
between neutrophils undergoing NETosis and neutro-
phils undergoing necrosis. As shown in Supplementary
Figure 1B (available on the Arthritis & Rheumatology
web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39313/abstract), a significantly higher amount of sol-
uble extracellular DNA was released from neutrophils
after NETosis as compared to that in unstimulated cells
and that in necrotic cells (both P, 0.05).
Levels of free DNA in SF samples showed a
strong correlation with neutrophil cell counts in the SF of
RA patients (Figure 1C). In contrast, no correlation of
free DNA levels with macrophage counts in the RA SF
could be observed (Figure 1D). Moreover, no statistically
significant correlations between DNA levels in the RA
SF and clinical parameters, such as the Disease Activity
Score in 28 joints, the C-reactive protein level, or the
erythrocyte sedimentation rate, were observed.
Immunostaining of preparations of RA SF on
glass slides showed a network of extracellular DNA
strands, similar to that reported previously as a typical
feature of NETs in a range of studies. The findings from
immunostaining indicated that the extracellular DNA
colocalized with neutrophil elastase, a major constituent
of NETs, in the RA SF (Figure 2A). In frozen sections of
synovial tissue from patients with RA, neutrophil aggre-
gates were observed on the surface of the synovial lining,
facing the joint cavity. As shown in Figure 2B, these
aggregates stained positive for CD15 and neutrophil elas-
tase. Extracellular DNA and citrullinated histone H3, a
hallmark of NETosis, were observed to be associated
with these aggregates (Figure 2B). These results are con-
sistent with the concept that extracellular DNA and
NETs are associated with the localization and number of
neutrophils present in the SF of patients with inflamma-
tory arthritis.
In vitro PAD release during NETosis. Several
of the proteins (e.g., fibrinogen and collagen) that can
be converted into autoantigens by citrullination are pre-
dominantly located in the extracellular space. To under-
stand the production of these citrullinated neoantigens,
it is important to investigate sources of extracellular
PAD. Since NETosis involves release of cellular compo-
nents, we investigated whether neutrophils undergoing
NETosis would release PAD into the extracellular
space. In order to assess the release of unbound PAD
into the supernatant and its attachment to NETs, an in
vitro assay of NET isolation and detection was devel-
oped based on a previously published method (18).
To validate the assay, DNA release during NETosis was
assessed over a time course of up to 240 minutes (Figure
3A), and DNA levels in the fractions generated during
NET isolation were tracked (Figure 3B). As shown in
Figure 3B, only a small proportion of the DNA was
detectable in the supernatant of stimulated neutrophils,
suggesting that NETs are largely still attached to the
neutrophil layer at this stage.
The stimulation was followed by 3 washing steps
to ensure that only proteins attached to NETs were isolat-
ed. DNase I treatment released a fraction containing sig-
nificantly higher levels of DNA compared to the fraction
derived from DNase I–treated unstimulated neutrophils
Figure 2. Detection of neutrophil extracellular traps in the synovial
fluid (SF) of patients with rheumatoid arthritis (RA) and attached
to the synovial tissue of RA patients. A, SF preparations from 17
RA patients were stained for extracellular DNA (gray) and neutro-
phil elastase (NE) (green). B, Neutrophil aggregates attached to the
synovial tissue of 3 RA patients were detected by confocal laser
scanning microscopy. Samples were labeled with antibodies specific
for CD15, NE, and citrullinated histone 3 (cit H3) (green) as well as
for DNA (gray and blue). Original magnification 3 630.
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or the fraction derived from stimulated neutrophils incu-
bated without DNase I (Figure 3B).
Both PAD2 and PAD4 were detected in the
supernatant of stimulated neutrophils and in the NET
fraction, suggesting that PAD2 and PAD4 are both
released as freely diffusible proteins as well as bound to
NETs (Figure 3C). Importantly, the antibodies used to
detect PAD2 and PAD4 did not show cross-reactivity
(Figure 3C).
To validate our results, a quantitative proteomics
analysis was performed. Consistent with the findings
from a study by Urban et al (18), only a small number of
proteins, comprising mainly granular and nuclear pro-
teins, could be confirmed to be present in NETs, as com-
pared to the wide range of proteins released into the
supernatant during NETosis (see Supplementary Table 1,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39313/abstract).
Figure 3. Release of peptidyl arginine deiminases (PADs) into the supernatant during NETosis, and detection of enzymatically active PADs. A,
DNA release in peripheral blood neutrophils from healthy donors that were left unstimulated or stimulated with 25 mM phorbol myristate ace-
tate (PMA) was assessed for up to 240 minutes after stimulation. Bars show the mean6 SD of 8 samples per group. B, For isolation of neutro-
phil extracellular traps, supernatants (SN) of unstimulated (unst.) or stimulated (stim.) neutrophils were collected. Subsequently, the cells were
washed 3 times with RPMI medium (W1–W3), and stimulated cells were incubated in the absence or presence of DNase I; unstimulated cells
treated with DNase I served as a control. Bars show the mean6 SD DNA concentration (conc) in 7 samples per group. C, Proteins (PAD2,
PAD4, and neutrophil elastase [NE]) were precipitated from the same supernatants of unstimulated or stimulated cells as described in B and
analyzed by Western blotting. Citrullinated proteins (citr.prot.) were detected using chemical modification and anti–modified citrulline antibody.
PAD2 and PAD4 antibodies were tested for cross-reactivity using human (hu) recombinant PAD4 (rPAD4) (250 ng) and human skeletal muscle
tissue lysate (15 mg). One representative blot of 4 independent experiments is shown for each group. D, PAD activity in supernatants of unstimu-
lated and stimulated cells was compared. Symbols represent individual donors (n5 10); bars show the median. *5P , 0.05; **5P , 0.01, by Wilcox-
on’s matched pairs signed rank test. AFU5 arbitrary fluorescence units; NS5 not significant.
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Consistent with the findings from Western blot analysis,
PAD2 and PAD4 were detected in both the supernatant and
the DNase I–treated NET fraction of neutrophils from 7
patients. PAD2 was more abundant in the supernatant,
whereas PAD4 was more abundant in the NET fraction (see
Supplementary Table 1).
To test whether the activation of PAD isoforms
during NETosis would result in the generation of citrul-
linated proteins, proteins from the culture supernatants
were modified according to the protocol described by
Senshu et al (22) and detected using an anti–modified
citrulline antibody. As shown in Figure 3C, a large num-
ber of citrullinated proteins were released from stimu-
lated neutrophils into the supernatant after 4 hours,
compared to only a small number of citrullinated pro-
teins present in the DNase I–treated NET fraction of
stimulated neutrophils. Consistent with these findings,
citrullinated peptides from several proteins could be
identified by mass spectrometry (see Supplementary
Table 2, available on the Arthritis & Rheumatology web
site at http://onlinelibrary.wiley.com/doi/10.1002/art.39313/
abstract).
Furthermore, analysis of PAD activity with a
recently developed assay (23) showed higher levels of
PAD activity in the supernatants of stimulated neutro-
phils after 2.5 hours of stimulation in vitro, compared to
that in supernatants of unstimulated cells (Figure 3D).
PAD activity was also observed in the supernatants of
Figure 4. Time course of peptidyl arginine deiminase 2 (PAD2) and
PAD4 release during NETosis. Unstimulated (unstim.) peripheral
blood neutrophils from healthy donors and neutrophils at 30, 120, or
240 minutes after stimulation were assessed by confocal microscopy,
revealing that a proportion of cells enter NETosis after 120 minutes of
stimulation. In resting neutrophils, PAD2 is seen only in the cytosol,
whereas PAD4 is localized in the nucleus. PAD2 levels drop within 30
minutes after stimulation, and PAD4 is lost from the nuclei of cells
undergoing DNA decondensation. No PAD4 signal can be detected
after 240 minutes of stimulation; these cells have reached a stage of
NETosis at which the nuclear morphology has changed. DNA is shown
in blue, PAD2 in green, PAD4 in red, and colabeling with neutrophil
elastase (NE) in green. Insets show higher-magnification views. Origi-
nal magnification3 400;3 1,200 in insets.
Figure 5. Detection of enzymatically active peptidyl arginine deimi-
nase (PAD) in the synovial fluid (SF) of patients with rheumatoid
arthritis (RA). A, Immunoblotting of albumin-depleted SF samples
from 8 RA patients shows presence of neutrophil elastase (NE),
PAD4, and PAD2. B, PAD activity in the SF of patients with RA
(n5 12) was significantly higher than that in the SF of patients with
osteoarthritis (OA) (n5 9). C, PAD activity was observed in the OA
SF and RA SF both at physiologic calcium concentrations and at
higher calcium concentrations (5 mM). In B and C, symbols repre-
sent individual patients; horizontal bars show the median. D, PAD
activity is significantly correlated with DNA levels in the SF of RA
patients (n5 22). Data were analyzed using Spearman’s rho test for
correlation. *5P , 0.05; **5P , 0.01, by Mann-Whitney U test.
ENZYMATICALLY ACTIVE PADs AND AUTOANTIGEN PRODUCTION IN RA SF 3141
necrotic cells (see Supplementary Figure 1C, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.39313/abstract).
Localization of PAD2 and PAD4 within the neu-
trophils undergoing NETosis was visualized by immu-
nofluorescence staining (Figure 4). While PAD2 was
largely restricted to the cytosol, PAD4 localization in
resting peripheral blood neutrophils was found to be
restricted to the cell nucleus, findings that were consis-
tent with those in a study by Nakashima et al (24). Upon
stimulation of the cells for 120 and 240 minutes, a pro-
portion of the cells had changed their nuclear morphol-
ogy. Nuclei were rounded and decondensed, indicating
a stage of NETosis directly preceding DNA release (Fig-
ure 4). PAD2 staining was reduced within 30 minutes of
stimulation, while PAD4 staining was lost from the
nuclei, together with evidence of DNA decondensation.
These results suggest that upon activation, neutrophils
entering NETosis activate PAD isoforms, leading to cit-
rullination of a large number of neutrophil proteins and
also release of active PAD into the extracellular space.
Evidence of enzymatically active PAD in RA
SF. In accordance with the results from a study by Kin-
loch et al (25), PAD2 and PAD4 proteins were detected
in the cell-free SF of patients with RA, in addition to
the presence of neutrophil elastase (Figure 5A). Where-
as PAD4 varied in its expression level, the amount of
PAD2 was found to be more similar between patients.
Furthermore, PAD enzymatic activity was significantly
higher in the SF of RA patients than in the SF of OA
patients (P , 0.05) at the supraphysiologic calcium con-
centrations used in this assay (Figure 5B). Interestingly,
this significant difference between RA and OA could
also be observed in undiluted SF samples at their native
calcium concentrations, with PAD activity in the OA SF
samples being ;250-fold lower than in the RA SF sam-
ples (Figure 5C).
Furthermore, PAD activity in fresh, untreated SF
samples from patients with RA strongly correlated with
not only the levels of extracellular DNA (r5 0.8, P ,
0.0001) (Figure 5D) but also the neutrophil counts
(r5 0.8, P5 0.002) and total cell counts (r5 0.72, P5
0.002) (see Supplementary Figures 1D and E, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.39313/abstract).
DISCUSSION
The generation of citrullinated autoantigens after
protein deimination by PAD is a key stage in the auto-
immune response in ACPA-positive patients with RA
(8). Nevertheless, the mechanisms behind the activation
of PAD, as well as the sites and circumstances of citrulli-
nation of autoantigens in RA, have remained unclear.
In this study, NETosis was identified as a source
of freely diffusible, enzymatically active PAD, as well as
a source of citrullinated proteins, suggesting that neu-
trophils have a central role in the generation of autoan-
tigens. Neutrophils are the most abundant cell type
present in the SF of patients with RA (11,26). Evidence
from this and other studies shows that neutrophils
undergo NETosis at the site of inflammation and there-
by release decondensed DNA (5,27–29).
Extracellular DNA was observed within neu-
trophil infiltrates attached to the surface of the synovial
lining layer and in SF preparations. Our study cannot
exclude the possibility of cells other than neutrophils
contributing to the production of extracellular DNA and
to PAD activity in the SF of RA patients. As described
previously, monocytes and macrophages can be a source
of PAD (30), and cells such as eosinophils, mast cells, or
macrophages can release their chromatin in a process
related to NETosis (31). However, eosinophils and mast
cells are present in only very low numbers in RA SF
(32). In the present study, extracellular DNA levels in
the RA SF showed no significant correlation with mac-
rophage counts, whereas there was a highly significant
association between DNA levels and neutrophil num-
bers. Comparison of neutrophils undergoing necrosis
and those undergoing NETosis showed that there is sig-
nificantly less release of soluble extracellular DNA from
necrotic neutrophils. This difference may be explained
by the high level of nuclear decondensation during the
process of NETosis.
Consistent with our finding of PAD activity in the
SF, several studies have already described the presence
of citrullinated proteins in the SF of patients with inflam-
matory arthritis (25,33,34). Interestingly, some of these
targets, such as citrullinated myeloid nuclear differen-
tiation antigen or vimentin, were also generated during
in vitro NETosis in our assay, thus further supporting the
idea that NETs are a possible source for these citrullin-
ated proteins in the joints. This is also consistent with
other published work in which citrullinated proteins with-
in NETs were described as targets of the autoimmune re-
sponse both in RA and in Felty’s syndrome (35,36).
The number of citrullinated proteins identified in
the present study was fairly small. The very rigorous vali-
dation process used to minimize false-positive results, as
described in the Supplementary Methods and Tables,
may have contributed to this low number. The view that
NETosis contributes to citrullination was also supported
by findings from a study by De Rycke et al, in which
localization of citrullinated proteins within extrasynovial
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deposits of polymorphonuclear cells was observed on the
surface of the lining layer in RA patients (37).
Our data indicate that extracellular DNA levels
and neutrophil concentrations in the SF correlated with
PAD activity, which further supports the proposition
that PADs are released and activated as a result of
NETosis in the joints of patients with RA, in contrast to
that observed in the SF of patients with OA, which
showed minimal PAD activity. Release of PAD activity
was also observed under conditions of induced necrosis
in vitro. This is likely to involve release of cytosolic
PAD2 after loss of membrane integrity.
PAD enzymatic activity is regulated by calcium
ions (38). Indeed, intracellular Ca21 levels were below
the level needed for in vitro PAD activity, indicating that
further, as-yet undefined, regulatory mechanisms may be
operating in the joints. Thus, in vitro PAD activity was
initially measured at supraphysiologic calcium concentra-
tions. However, although the PAD activity measured in
RA SF at physiologic calcium concentrations was lower,
it was still detectable with the ABAP assay used in this
study and was significantly higher than that in OA SF.
This observation was also confirmed in a recent small
study using human fibrinogen as the substrate for PAD
activity (39). In accordance with our data, calcium con-
centrations in RA SF samples in that study were found to
be still sufficient to support PAD activity (39). It can
therefore be concluded that the conditions for optimal
activity in vitro differ from the conditions in vivo.
In this regard, a recent study by Darrah et al dem-
onstrated a mismatch between the in vitro and in vivo cal-
cium requirements for PAD4 activity, and explained this
by the presence of PAD3/PAD4 cross-reactive antibodies
that may have a major role in decreasing the enzyme’s
requirement for calcium concentrations into the physio-
logic range in vivo (40). Moreover, recombinant and
native PAD may differ in folding, posttranslational modi-
fication, and specific activity, further complicating the
interpretation of the calcium dependency across experi-
ments. More relevant for the patient, however, is the
observation that PAD activity is being generated under
the conditions present in the inflamed joint. Future stud-
ies will be needed to identify the contribution of different
isoenzymes to the overall PAD activity observed during
NETosis and to investigate regulatory factors that might
modulate the enzymatic activity.
Since the assay used for measuring PAD activity
does not distinguish between different PAD isoforms, it
is possible that there is a separate, unique contribution to
total PAD activity by PAD2, PAD3, and PAD4. Interest-
ingly, mass spectrometry did not identify any unique pep-
tides matching PAD3 as being present in neutrophils.
Identification of the PAD isoforms that are responsible
for the observed PAD activity is of interest, because it
was recently reported that different PAD enzymes dis-
play distinct substrate specificities (41) and could there-
fore lead to the citrullination of different autoantigens.
Several studies have recognized the absence of
synovial inflammation (histologically and by imaging) in
individuals who have RA-specific autoantibodies and joint
pain but no clinically apparent joint swelling (42–44), and
these studies therefore propose the concept that the initi-
ating event leading to ACPA production is more likely to
be located outside the joint. In this context, Rosenstein
et al first hypothesized that the generation of citrullinated
antigens by PPAD, the bacterial PAD enzyme derived
from Porphyromonas gingivalis in periodontal tissue, could
be a potential trigger for the initiation of ACPAs (45). In
addition, the lungs have also been suggested to play a role
in triggering the autoimmune response to citrullinated
proteins (46). Based on findings of the presence of NETs
in inflamed gingival crevicular fluid (29) and lungs (28), it
is therefore also possible that PAD release during NETo-
sis contributes to generation of citrullinated proteins initi-
ating the ACPA response at these sites. In addition, other
mechanisms, such as the generation of major histocomp-
ability complex–citrullinated peptide complexes in auto-
phagosomes of antigen-presenting cells leading to the
induction of autoimmunity, are possible (47).
We therefore do not propose that production of
citrullinated proteins during NETosis in the joint represents
the original breakdown of immune tolerance to citrullinated
proteins. Rather, we suggest that release of PAD from neu-
trophils in the joints of RA patients represents a later event
in the disease process, during which citrullinated proteins
and preexisting ACPAs form proinflammatory immune
complexes and drive a continuous inflammatory response
in the joints, which may be supported by our finding of sig-
nificantly higher DNA levels in ACPA-positive RA patients
compared to ACPA-negative RA patients. In this context,
findings of a recent study suggesting that PAD4 is not
essential for disease in the murine K/BxN autoantibody-
mediated model of arthritis does not conflict with our
observations, as this model does not depend on autoimmu-
nity to citrullinated proteins (48).
NETosis may not be the only source of citrullin-
ated proteins in the joints of patients with inflammatory
arthritis. Intracellular citrullination was reported in sev-
eral cell populations in the synovium (12,49) and in SF
cells (50), and release of enzymatically active PAD
could also be observed in our study after the induction
of necrosis. Cell lysis induced by immune-mediated
membranolytic pathways, for example, could represent
another source of PAD and citrullinated proteins (50).
ENZYMATICALLY ACTIVE PADs AND AUTOANTIGEN PRODUCTION IN RA SF 3143
Nevertheless, further studies are needed to examine the
mechanisms underlying the initial intracellular activa-
tion of PAD in relation to different cell death pathways.
ACPAs are enriched in SF compared to serum (51),
and B cell clones specific for citrullinated proteins persist in
the inflamed synovium of RA patients (10). This local im-
mune response requires continuous production of citrul-
linated antigens in the joint. We therefore propose that
activated neutrophils undergoing NETosis in the joints of
patients with RA contribute to this supply of autoantigens
by the release of enzymatically active PAD isoforms.
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